2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.Peer-Reviewed Original ResearchConceptsSocioecological modelGermline testingHealthcare institutionsCancer genetic testingHereditary cancer implicationsEquity frameworkBlack malesCancer screeningReduce disparitiesBackgroundBlack menCommunity liaisonCommunity stakeholdersMixed-methods approachOvercome barriersImprovement PartnershipCommunity eventsCascade testingModified Delphi modelRate of prostate cancerGenetic testingCancer implicationsEducation programsBlack menEquitable strategiesIncreased engagementBRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients
Cheng H, Shevach J, Castro E, Couch F, Domchek S, Eeles R, Giri V, Hall M, King M, Lin D, Loeb S, Morgan T, Offit K, Pritchard C, Schaeffer E, Szymaniak B, Vassy J, Katona B, Maxwell K. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients. JAMA Oncology 2024, 10: 1272-1281. PMID: 39052257, DOI: 10.1001/jamaoncol.2024.2185.Peer-Reviewed Original ResearchBRCA1/2 PVCancer riskPoly ADP-ribose polymeraseGenetic testingCancer genetic testingFamilial cancer riskPrimary care cliniciansEvidence of increased riskBRCA1/2-PV carriersMale carriersIncreased genetic testingRisk of breastRisk reductionCancer early detectionCancer-predisposing variantsClinical trial opportunitiesCancer therapy optionsCare cliniciansTargeted risk managementCancer screeningPV carriersHereditary cancerADP-ribose polymeraseGuideline recommendationsEarly cancer detectionHealth care utilization and behavior changes after workplace genetic testing at a large US health care system
Charnysh E, Pal S, Reader J, Uhlmann W, McCain S, Sanghavi K, Blasco D, Brandt R, Feero W, Ferber R, Giri V, Hendy K, Prince A, Lee C, Roberts J, consortium I, Crumpler N, Leader A, Mathews D, Ryan K, Spector-Bagdady K, Vogle A, Brothers K, Clayton E, Deverka P, Ellis T, Goldenberg A, Mockus S, Morton C, Rueter J, Witham B, Bessey E, Gordon E, Lee L, Roberts J, Saidi F. Health care utilization and behavior changes after workplace genetic testing at a large US health care system. Genetics In Medicine 2024, 26: 101160. PMID: 38733246, DOI: 10.1016/j.gim.2024.101160.Peer-Reviewed Original ResearchHealth behavior changeU.S. healthcare systemHealthcare utilizationIncreased riskAssociated with health behavior changesBehavioral changesHealthcare systemPromote health behavior changeGenetic testingImprove employee healthHeart diseaseSelf-reported dataLogistic regression analysisElectronic surveyMedication changesDescriptive statisticsHealthcarePGx resultsEmployee healthHealth implicationsRegression analysisHealthPGxWorkplaceCancerTARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testing
2023
Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Giri V, Keith S, Cheng H, Leader A, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Loeb S. Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 10598-10598. DOI: 10.1200/jco.2023.41.16_suppl.10598.Peer-Reviewed Original ResearchDecisional conflictGenetic testingPre-test genetic counselingGermline testingGenetic counselingProstate cancerRandomized non-inferiority trialHereditary cancer risk assessmentGermline genetic testingClinical trial eligibilityNon-inferiority trialProstate Cancer FoundationProstate cancer managementCancer genetic testingDecision Conflict ScaleCancer risk assessmentGermline evaluationTrial eligibilityPrimary endpointMean ageStudy protocolCancer managementGenetics educationAnalysis of covarianceCancer Foundation
2022
Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families
Leader A, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri V. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal Of Community Genetics 2022, 13: 547-556. PMID: 35869324, PMCID: PMC9681950, DOI: 10.1007/s12687-022-00603-1.Peer-Reviewed Original ResearchGenetic test resultsProstate cancerGenetic testingDiagnosis of PCaFamily membersClinical trial optionsGermline genetic testingPV/LPVRelevant family membersGenetic testing experiencesImmediate family membersPCa patientsCancer screeningPatientsTrial optionsPrecision therapyGenetic resultsGenetic counselorsTesting experienceThematic analysisCommunication barriersSemi-structured interviewsParticipantsTherapyTestingPatient-reported outcomes among males undergoing prostate cancer germline testing: Interim results from the Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) Registry.
Giri V, Hartman R, Gross L, Keith S. Patient-reported outcomes among males undergoing prostate cancer germline testing: Interim results from the Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) Registry. Journal Of Clinical Oncology 2022, 40: 10595-10595. DOI: 10.1200/jco.2022.40.16_suppl.10595.Peer-Reviewed Original ResearchPatient-reported outcomesGermline testingGenetic testingPROGRESS registryDecisional conflictNon-Hispanic/LatinoDiagnosis of PCaCancer genetic riskGenetic counselingCancer geneticsPatient experience informationStudy registryGleason scoreRegistry participantsFamily historyRegistryGenetic resultsAfrican American malesCategorical variablesGenetic riskSAS 9.4Traditional genetic counselingDemographic informationGenetic mutationsMenGermline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing
Giri V, Hartman R, Pritzlaff M, Horton C, Keith S. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology 2022, 6: e2200234. PMID: 35666082, PMCID: PMC9200399, DOI: 10.1200/po.22.00234.Peer-Reviewed Original ResearchConceptsGermline testingAA menWhite menHereditary cancer assessmentStandard clinical testingCohort of menAfrican American menGermline evaluationMultivariable analysisClinical managementBorderline associationLP variantsVariant statusClinical testingGermline analysisPanel testingRate of variantsCare deliveryVariant spectrumGenetic testingCancer assessmentUncertain significanceDNA repair genesGenetic counselingAmerican menGermline testing and genetic counselling in prostate cancer
Russo J, Giri V. Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology 2022, 19: 331-343. PMID: 35449224, PMCID: PMC9022414, DOI: 10.1038/s41585-022-00580-7.Peer-Reviewed Original ResearchConceptsProstate cancerCancer risk managementCancer riskGenetic testingHereditary cancer predisposition syndromesPre-test discussionUnique clinical featuresGermline pathogenic variantsPrecision medicineHealth care professionalsComplex management optionsAdditional cancer riskCancer predisposition syndromeHereditary cancer riskGenetic counsellingGermline testingMetastatic diseaseClinical featuresOptimal careMedical historyFamily historyPathogenic variantsPrecision therapyGene testingCancerGenetic testing in prostate cancer management: Considerations informing primary care
Giri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNational Comprehensive Cancer Network guidelinesProstate cancerPrimary careGenetic testingNetwork guidelinesFamily historyClinical trial optionsGermline genetic testingMetastatic prostate cancerPrimary care providersMultidisciplinary patient careProstate cancer managementRole of cliniciansHereditary cancer riskMultiple professional societiesComprehensive family historyPC survivorsGermline testingPC screeningAggressive diseasePoor outcomePC careClinical pathwayCancer managementCancer riskVirtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study.
Giri V, Gross L, Cheng H, Russo J, Paller C, Johnson J, Weg E, Loeb S. Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study. Journal Of Clinical Oncology 2022, 40: 184-184. DOI: 10.1200/jco.2022.40.6_suppl.184.Peer-Reviewed Original ResearchMetastatic prostate cancerProstate cancerGermline testingGenetic counselingRisk of PCaEarly-stage prostate cancerBaseline surveyHigh-risk diseaseStandard of careCancer genetic testingCancer genetics knowledgeMedical oncologistsMedical oncologyClinical trial managementClinical trialsNurse practitionersCancer managementAcademic centersFavorable responseCase discussionRadiation oncologistsPCa screeningKnowledge scoreGenetic testingPractice settings
2021
Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice
Giri V, Walker A, Gross L, Trabulsi E, Lallas C, Kelly W, Gomella L, Fischer C, Loeb S. Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clinical Genitourinary Cancer 2021, 20: e104-e113. PMID: 35012874, DOI: 10.1016/j.clgc.2021.11.009.Peer-Reviewed Original ResearchConceptsGermline testingFamily historyClinical practiceChronic Diseases frameworkMultiple family historyMaternal family historyCancer genetic testingMedical oncologistsAdvanced PCaPCa riskProvider interviewsAggressive PCaRadiation oncologistsPractice settingsGenetic testingLarger studyDisease frameworkClinical useOncologistsLower ratesPractice gapMenDescriptive statisticsPhiladelphia areaProvidersPredictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine.
Giri V, Shimada A, Leader A. Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. JCO Precision Oncology 2021, 5: 1699-1708. PMID: 34778693, PMCID: PMC8585288, DOI: 10.1200/po.21.00231.Peer-Reviewed Original ResearchConceptsExact testCancer informationMultivariate logistic regression modelPopulation-based studyCross-sectional studyFisher's exact testPopulation-based sampleGenetic awarenessNational Trends SurveyNon-Hispanic whitesLogistic regression modelsPrecision medicine eraMiddle-high incomeDiverse population-based sampleCancer careModifiable factorsPersonalized cancer treatmentCancer preventionFemale genderHealth literacyCancer fatalismMedical literacyMultivariate analysisEthnic disparitiesGenetic testingAdopting Consensus Terms for Testing in Precision Medicine
Martin N, Tepper J, Giri V, Stinchcombe T, Cheng H, Javle M, Konnick E. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precision Oncology 2021, 5: 1563-1567. PMID: 34651094, PMCID: PMC8509918, DOI: 10.1200/po.21.00027.Peer-Reviewed Original ResearchConceptsGenetic testingTreatment decisionsOncology health care providersHealth care providersPrecision medicineLow socioeconomic statusPreferred termPatient advocacy groupsGermline testingTumor characteristicsOncology carePatient preferencesBiomarker testingPatient educationCancer riskCare providersPatient confusionSolid tumorsBlood cancersGermline mutationsGermline variantsAppropriate testingPatientsSocioeconomic statusGenomic testingGaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis
Loeb S, Massey P, Leader A, Thakker S, Falge E, Taneja S, Byrne N, Rose M, Joy M, Walter D, Katz M, Wong R, Selvan P, Keith S, Giri V. Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. JMIR Cancer 2021, 7: e27063. PMID: 34542414, PMCID: PMC8550715, DOI: 10.2196/27063.Peer-Reviewed Original ResearchProstate cancerBreast cancerGenetic testingHereditary cancer riskBreast cancer contentGermline testingPCa managementCancer riskHealth professionalsBRCACancerBreastcancerCancer contentProstatecancerPublic awarenessPopulation awarenessSearch termsPrecision medicineSubset of tweetsTotal numberTestingGreater reachBRCA1/2Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.
Peters C, Turner C, Chesnut G, Giri V, Gomella L, Shriver C, Dobi A. Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine. Canadian Journal Of Urology 2021, 28: 10659-10667. PMID: 34129457.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsBarriers and facilitators of germline genetic evaluation for prostate cancer.
Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng H, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. Journal Of Clinical Oncology 2021, 39: 28-28. DOI: 10.1200/jco.2021.39.6_suppl.28.Peer-Reviewed Original ResearchCoordination of careProstate cancerGenetic testingChronic Diseases frameworkGuideline-concordant careGermline genetic testingMetastatic prostate cancerGenetic counselingGermline testingLocalized diseasePatient factorsMedical oncologistsTherapeutic optionsCancer screeningPhysicians' knowledgeCurrent guidelinesPhysician educationRecent approvalRadiation oncologistsPractice settingsCancerDisease frameworkThematic saturationProstate Cancer GeneticsGenetic evaluation
2020
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb S, Giri V. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology 2020, 4: 1-9. PMID: 33390340, DOI: 10.1016/j.euo.2020.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingLocalized diseaseMetastatic PCaFamily historyGermline evaluationMetastatic diseaseCurrent guidelinesProstate cancerCancer riskPractice settingsGenetic testingDNA mismatch repair deficiencyManagement of menProstate cancer managementFamily cancer riskEarly-stage PCaMismatch repair deficiencyHereditary cancer riskPathologic featuresHistologic featuresMedical oncologyCancer screeningPCa managementPCa riskConsensus panelPractical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice 2020, 16: 811-819. PMID: 32986533, PMCID: PMC7735040, DOI: 10.1200/op.20.00431.Peer-Reviewed Original ResearchConceptsGermline genetic testingProstate cancerGenetic testingNumber of patientsCritical unmet needCurrent guidelinesTesting deliveryPatientsUnmet needPrecision oncologyGenomic testingGenetic counselingGenetics providersGenetic servicesClinical workflowCancerOncologyLimited accessWorking GroupGuidelinesStandardized systemProvidersTestingClinic